Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals Announces Inducement Grants The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering


Crinetics closed an underwritten public offering of 5,625,563 shares of its common stock, resulting in gross proceeds of approximately $125.0 million.

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering


announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share.

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Reports Positive Top-Line Results from CRN04777 Phase 1 MAD Cohorts


Crinetics ($CRNX) reports results from CRN04777 Phase 1 MAD study that support potential to treat hyperinsulinism regardless of underlying genetic mutation